Lunai Bioworks Inc. (NASDAQ:LNAI) said its subsidiary BioSymetrics has signed a multi-year commercial partnership with a biotechnology company to develop an artificial intelligence–enabled platform focused on assessing chemical threats.
Under the collaboration, BioSymetrics will apply its phenotypic screening technology and AI capabilities to detect and categorize neuroactive and neurotoxic compounds. The initiative expands Lunai Bioworks’ footprint in defense and national security–related applications.
BioSymetrics plans to integrate zebrafish-based phenotypic screening with AI-powered mechanism-of-action modeling to analyze chemical compounds. According to the company, the platform is capable of evaluating hundreds to thousands of compounds each week.
The project will involve experimental screening of agents affecting the central nervous system, computational modeling to predict mechanisms of action, and the integration of biological and analytical datasets. The goal is to improve the identification and characterization of neuroactive and toxic substances.
“This collaboration reflects Lunai Bioworks’ commitment to applying cutting-edge AI and phenotypic science to real-world challenges in global security,” said David Weinstein, chief executive officer of Lunai Bioworks. “BioSymetrics’ platform is uniquely positioned to bridge experimental biology and machine learning, enabling faster and more reliable insights into complex chemical threats.”
The initiative aligns with Lunai Bioworks’ strategy of advancing dual-use technologies that serve both defense and pharmaceutical sectors, including areas such as toxicity prediction, drug safety and neurobiology. The company added that the collaboration will generate revenue, with additional potential engagements currently under discussion.